Federal contract award
75F40121P00621
ANALYSIS OF ADDERALL AND GENERICS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 518210 — Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services |
| PSC | B529 — Scientific Data Studies |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $362.4K |
| Current contract value | $362.4K |
| Potential contract value / ceiling | $362.4K |
| Start date | Sep 21, 2021 |
| Current end date | Mar 20, 2028 |
| Potential end date | Mar 20, 2028 |
| Latest award activity | Aug 27, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 15 of 15 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 27, 2026 | P00014 | $0 | EO 14398 - THE PURPOSE OF THE MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE BY 18 MONTHS (09/21/2021 - 09/20/2026 TO 09/21/2021 - 03/20/2028). |
| Sep 23, 2025 | P00013 | $0 | UPDATE SOW AND CHANGE COR |
| Mar 10, 2025 | P00012 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Jan 14, 2025 | P00011 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Apr 24, 2024 | P00010 | $0 | THIS MODIFICATION IS TO CLARIFY THE EXPECTATIONS ON THE DELIVERABLE ITEMS. |
| Sep 12, 2023 | P00009 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Aug 14, 2023 | P00008 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Jul 17, 2023 | P00007 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Jun 12, 2023 | P00006 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| May 19, 2023 | P00005 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Apr 28, 2023 | P00004 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Apr 4, 2023 | P00003 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Mar 20, 2023 | P00002 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Mar 28, 2022 | P00001 | $0 | ANALYSIS OF ADDERALL AND GENERICS |
| Sep 21, 2021 | 0 | $362.4K | ANALYSIS OF ADDERALL AND GENERICS |
Estimated positioning window
Mar 20, 2027 – Sep 20, 2027
55/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 55/100. Available recorded signals: 50 points.
- Contract end 2028-03-20 (512 days from calculation)
- +25 points
- 2 historical awards in this buyer and category group
- +10 points
- 15 recorded award transactions
- +10 points
- Latest award action: 2026-08-27
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.